Abstract
Treatment with the sphingosine 1-phosphate (S1P) receptor modulator, RPC1063, resulted in a substantial decrease in gadolinium-enhancing (Gd+) lesions and the number of new or enlarging T2 lesions in patients with relapsing-remitting multiple sclerosis (RRMS). This article presents data from the Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients trial [Radiance Study; NCT01628393].
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
